Navigation Links
Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer
Date:9/21/2011

the incidence of sepsis in wounded warfighters through the selective clearance of circulating septic precursors.  

The genesis of the ADAPT™ system is the Hemopurifier®, a device that immobilizes a single lectin affinity agent to provide broad-spectrum capabilities against viral pathogens and immunosuppressive proteins. Human studies have demonstrated the Hemopurifier® to be safe and provide average viral load reductions of greater than 50% during four-hour treatment periods in both hepatitis-C (HCV) and HIV infected individuals without the administration of antiviral drugs.  The device is currently the subject of a human clinical study to evaluate its ability to accelerate viral load depletion when utilized in combination with HCV standard of care drug therapy.  An investigational device exemption (IDE) to initiate clinical studies in the United States has been submitted to The Food and Drug Administration (FDA).

In vitro studies recently documented that the Hemopurifier® also captures exosomes underlying cancer, including colorectal, lymphoma, melanoma, ovarian, and breast cancer. On August 24th, Aethlon expanded its exosome research programs through a collaborative agreement with the Sarcoma Oncology Center (SOC), based in Santa Monica, California. The SOC collaboration will study the ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.  The study will evaluate 25 patients, five patients with metastatic cancer of the following types; non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma.  Exosomes released by cancers have emerged to become an important therapeutic target in cancer care, as they are implicated in cancer survival, growth, and metastasis.  Researchers have also identified that cancer-released exosomes may assist tumors in evading the resp
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
2. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
3. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
4. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
5. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
6. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
7. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
8. Aethlon Medical Reestablishes Biodefense Programs
9. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
10. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
11. Aethlon Medical Names Rod Kenley President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)...  An International Trade Commission (ITC) ruling issued Friday ... device, Taiwanese device manufacturer APEX continues to infringe ResMed ... ) is the innovation leader and pioneer in designing ... "Our research and development teams are ... of comfort, performance and efficacy," said David Pendarvis ...
(Date:7/21/2014)... Apex Medical Corporation (Apex, TWSE: 4106), a leading player ... announces that the United States International Trade Commission (USITC) ... newly designed XT series continuous positive airway pressure (CPAP) ... the patent claims asserted by ResMed, one of Apex,s ... an upgraded iCH water tank to the market in ...
(Date:7/18/2014)... 2014 Hanger, Inc. (NYSE: HGR ) ... operations for the quarter ended June 30, 2014, on Tuesday, ... to discuss these results is scheduled to begin at 9:00 ... participate should call 1-877-662-6095. A replay will be available until ... ID # 44683027. About Hanger, Inc. – Built ...
Breaking Medicine Technology:ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2Apex Medical's Respiratory Therapy Product Receives Affirmation from USITC 2
... an international generic pharmaceuticals company, today announced that ... Food & Drug Administration to market Zolpidem Tartrate ... the product has commenced.   Actavis ... Extended-Release Tablets 6.25 mg strength in October 2010 with ...
... 6, 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ... the Phase IB/II study of the Btk inhibitor, PCI-32765, ... (CLL/SLL) at the 2011 American Society of Clinical Oncology ... development program update for the Btk Inhibitor, PCI-32765.  The ...
Cached Medicine Technology:Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S. 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 7Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 8Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 9
(Date:7/21/2014)... July 21, 2014 What do romance, ... have in common? You can find them all in ... novel's main character, Miranda, lives on Martha’s Vineyard with ... a wealthy New Yorker, and becomes entangled in a ... Heart challenges readers to think about what choices they ...
(Date:7/21/2014)... (Philadelphia, PA) Patients who have a clot ... be treated with traditional blood-thinning medication or undergo ... comfortable that there is no difference in death ... more bleeding risks with the catheter procedure, according ... Medicine researchers. The study involved a review of ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Executives ... agency specializing in private healthcare practices, will participate ... (IACA). They will be showcasing their state-of-the-art capabilities ... medical practices all over the United States as ... efforts continues to increase. Advice Media’s presence at ...
(Date:7/21/2014)... MONDAY, July 21, 2014 (HealthDay News) -- The "viral ... avoiding detection and elimination, is established much earlier than ... poses new obstacles for those working to eradicate the ... Military HIV Research Program. They said the presence of ... finding a cure for a subtype of HIV, known ...
(Date:7/21/2014)... Public Affairs Research has released the results of a ... means to be a quality health care provider in ... Wood Johnson Foundation, sheds new light on how American ... doctors, as well as the information they use and ... new and actionable data during a crucial period of ...
Breaking Medicine News(10 mins):Health News:Thea Marsh Releases Debut Novel that Celebrates and Reaches out to Women Everywhere 2Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4Health News:Advice Media to Attend the International Association of Comprehensive Aesthetics Conference (IACA) Targeting the Dental Profession 2Health News:Animal Experiments Shed Light on HIV's Ability to Hide 2Health News:National survey from AP-NORC examines perceptions of health care provider quality 2
... Central government and striking medicos to end the agitation ... Castes// in educational institutes failed to reach any conclusion ... decision to implement the 27% reservation for OBCs in ... that they would plan to make their agitation 'more ...
... to a study it was found that a number ... measures, like a daily dose of aspirin, colon cancer ... young women, immunizing adults against the flu and pneumonia ... longer and healthier lives. The study’s results were published ...
... Ranbaxy Laboratories Limited today entered into an in-licensing agreement ... (NDDS) analgesic // , Tramadol in the Indian market ... the wholly-owned subsidiary of the French drug major for ... ,The product will be supplied from Ethypharm's manufacturing ...
... Laboratories Limited today said the World Health Organistion has ... products in its pre-qualification list. // ,The ... 200mg capsules, Stavudine 30mg capsules, Stavudine 40mg capsules, the ... significant development. We strongly feel that Generic ARVs are ...
... aroused as fear about childhood obesity grows and thus ... ... child-sized machines, during the past two years. ... Shokk and Zig Zag was building new facilities and installing machines for their little customers. ,According to ...
... Cabinet today cleared the business model for the state-of-the-art Institute ... the capital. // ,The model approved by the ... would enable the institute to be self-sufficient in nine years' ... the finances for procuring medical equipment would be borne by ...
Cached Medicine News:Health News:Disappointed Students Plan To Intensify Agitation Nationwide 2
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: